目的 回顧性研究分析疏風(fēng)解毒膠囊聯(lián)合阿比多爾治療新型冠狀病毒肺炎（COVID-19）的臨床療效。方法 選取2020年1月31日—2020年2月11日于COVID-19定點(diǎn)收治醫(yī)院亳州市人民醫(yī)院診斷并治療的COVID-19患者70例，按治療方法的不同，分為聯(lián)合用藥組（40例）和阿比多爾組（30例），兩組均予常規(guī)阿比多爾口服，聯(lián)合用藥組在此基礎(chǔ)上予口服疏風(fēng)解毒膠囊治療，療程10 d。對(duì)比兩組患者的退熱時(shí)間及干咳、鼻塞、流涕、咽痛、乏力、腹瀉等癥狀消失時(shí)間，比較兩組患者的新型冠狀病毒（SARS-CoV-2）轉(zhuǎn)陰率及轉(zhuǎn)陰時(shí)間。結(jié)果 聯(lián)合用藥組患者退熱時(shí)間及干咳、鼻塞、流涕、咽痛、乏力、腹瀉消失時(shí)間均較阿比多爾組顯著縮短（P<0.05），治療10 d后，聯(lián)合用藥組患者治愈出院6例，阿比多爾組出院1例；第10天復(fù)查咽拭子，聯(lián)合用藥組12例1次陰性、阿比多爾組7例1次陰性；聯(lián)合用藥組SARS-CoV-2轉(zhuǎn)陰時(shí)間較阿比多爾組顯著縮短（P<0.05）。結(jié)論 疏風(fēng)解毒膠囊聯(lián)合阿比多爾治療COVID-19優(yōu)于單用阿比多爾，能顯著縮短患者臨床癥狀的好轉(zhuǎn)時(shí)間和SARS-CoV-2轉(zhuǎn)陰時(shí)間。

Objective To observe the clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsule in the treatment of COVID-19. Methods From January 31, 2020 to February 11, 2020, 70 patients with COVID-19 diagnosed and treated in Bozhou people's hospital were selected. According to the different treatments, they were divided into two groups:40 patients in combination group and 30 patients in Arbidol Hydrochloride Capsule group. Patients in both groups were given routine Arbidol Hydrochloride Capsule orally. On this basis, the combination group was given oral Shufeng Jiedu Capsule for 10 d. The antipyretic time and the disappearance time of dry cough, nasal congestion, runny nose, sore throat, fatigue, diarrhea and other symptoms of patients in two groups were compared. The negative conversion ratio and negative conversion time of novel coronavirus (SARS-CoV-2) were also compared between two groups of patients. Results There were significant differences in antipyretic time, the disappearance time of dry cough, nasal congestion, runny nose, pharyngeal pain, fatigue, diarrhea, and novel coronavirus negative conversion time in the combination treatment group compared with the control group (P<0.05). The negative conversion time of combination treatment group was significantly shorter than Arbidol Hydrochloride Capsule group (P<0.05). Conclusion The combination of Shufeng Jiedu Capsule and Arbidol Hydrochloride Capsule was better than Arbidol Hydrochloride Capsule alone in the treatment of COVID-19, which could significantly shorten the symptoms improvement time and negative conversion time of the clinical patients.

R286

亳州市科技局重點(diǎn)研發(fā)項(xiàng)目（bzzc2019015）